SCHEDULE: Woodline Partners Discloses 9.9% Stake in SAB Biotherapeutics

Woodline Partners LP has reported a 9.9% beneficial ownership stake in SAB Biotherapeutics, Inc., primarily through common stock and convertible warrants.

Summary

• Woodline Partners LP, a Delaware limited partnership and investment adviser to Woodline Master Fund LP, filed a Schedule 13G.
• The filing reports beneficial ownership in SAB Biotherapeutics, Inc.'s Common Stock (par value $0.0001 per share, CUSIP 78397T202).
• Woodline Partners LP beneficially owns an aggregate of 7,125,881 shares of Common Stock.
• This ownership represents 9.9% of the class, calculated based on 45,108,294 shares of Common Stock outstanding as of September 30, 2025.
• The stake comprises 2,850,881 direct shares of Common Stock, 2,850,000 shares issuable from Enrollment Warrants (underlying 28,500 shares of Series B preferred stock), and 1,425,000 shares issuable from Data Release Warrants (underlying 14,250 shares of Series B preferred stock).
• The Series B Preferred Stock and warrants include 'Blockers' that prevent conversion or exercise if it would result in beneficial ownership exceeding 9.99% of the outstanding Common Stock.
• The reported aggregate amount of 7,125,881 shares is calculated without giving effect to these 'Blockers'.
• Woodline Partners LP holds sole voting power and sole dispositive power over all 7,125,881 shares.

Sentiment

Score: 7

Explanation: The filing indicates a substantial 9.9% beneficial ownership by Woodline Partners LP in SAB Biotherapeutics, which is generally a positive signal of institutional confidence. However, the presence of 'Blockers' limiting full conversion of warrants above a 9.99% ownership threshold introduces a minor constraint on the investor's potential influence or full realization of their stake.

Positives

• A significant institutional investor, Woodline Partners LP, has taken a substantial 9.9% stake in SAB Biotherapeutics, indicating potential confidence in the company's prospects.
• The investment structure, including common stock, enrollment warrants, and data release warrants, suggests a strategic, multi-faceted approach to their position.

Negatives

• The 'Blockers' provision limits Woodline Partners LP's ability to fully convert all warrants and preferred stock if it would result in ownership exceeding 9.99%, potentially restricting their upside or influence.
• The filing does not provide any financial performance details or operational updates for SAB Biotherapeutics, Inc.

Risks

• The Series B Preferred Stock, Enrollment Warrants, and Data Release Warrants contain 'Blockers' that prevent their conversion or exercise into Common Stock if such action would result in the holder (or its affiliates) beneficially owning greater than 9.99% of the outstanding Common Stock. This limits the full realization of potential ownership from these instruments if the threshold is met.

Future Outlook

N/A. This Schedule 13G filing reports beneficial ownership and does not contain forward-looking statements or guidance from the issuer or the reporting person regarding the issuer's future performance.

Industry Context

This filing indicates a significant institutional investor's stake in a biotherapeutics company. Such investments are common in the biotechnology sector, where early-stage companies often rely on institutional capital for research and development. The specific nature of the warrants (enrollment and data release) suggests a potential link to specific milestones or funding rounds typical in the biotech industry, aligning with venture or growth equity investment strategies.

Stakeholder Impact

• Shareholders: Existing shareholders may view Woodline Partners' significant stake as a vote of confidence, potentially influencing market perception and share price positively.
• Company Management: The presence of a large institutional investor like Woodline Partners may lead to increased scrutiny or engagement regarding corporate strategy and performance.

Key Dates

Recommendation

The disclosure of a 9.9% beneficial ownership by Woodline Partners LP, a sophisticated institutional investor, in SAB Biotherapeutics is a positive indicator of confidence in the company. While this filing does not provide operational or financial performance data to warrant a 'buy' or 'sell' recommendation, the substantial institutional backing suggests a 'hold' for existing investors, as it may signal potential future value or stability. New investors should conduct further due diligence beyond this ownership disclosure.

Keywords

SAB Biotherapeutics, Woodline Partners, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Series B Preferred Stock, Institutional Investor, Biotechnology